Bezuclastinib

Name: Bezuclastinib in Gastrointestinal stromal tumor: Access and distribution
Published: 2026-09-14T15:39:06-04:00

Gastrointestinal stromal tumor

Manufacturer: Cogent Biosciences
Regulatory submission: NDA submitted April 2026
Launch: Anticipated in the second half of 2026
Last updated: September 19, 2026

Section

Product information and disease description Product description Product information

Access and distribution

1 evidence topic · 1 source

Expanded access

“The patient must reside in the United States.” (opens the source at this quote in a new tab)
“Requests for expanded access must be submitted voluntarily by the patient’s treating physician.” (opens the source at this quote in a new tab)